Share class: Almirall, S.A.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 213,468,718 76,690,923 ( 35.93 %) 0 35.93 %

Major shareholders: Almirall, S.A.

NameEquities%Valuation
Grupo Corporativo Landon SL
58.95 %
125,845,628 58.95 % 1 572 M €
Norbel Inversiones SL
5.003 %
10,679,079 5.003 % 133 M €
Cobas Asset Management SGIIC SA
1.337 %
2,854,146 1.337 % 36 M €
1.266 %
2,703,324 1.266 % 34 M €
Caixabank Asset Management SGIIC SA
1.057 %
2,256,974 1.057 % 28 M €
Amundi Asset Management SASU (Investment Management)
0.6963 %
1,486,323 0.6963 % 19 M €
Bestinver Gestión SA SGIIC
0.5095 %
1,087,661 0.5095 % 14 M €
Mutuactivos SA SGIIC
0.4206 %
897,895 0.4206 % 11 M €
HSBC Global Asset Management (Switzerland) AG
0.4124 %
880,372 0.4124 % 11 M €
Sinergia Advisors 2006 AV SA (Investment Management)
0.2945 %
628,618 0.2945 % 8 M €
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Other63.95%
Institutional6.38%
Almirall SA1.27%
Unknown28.4%

Based on 1000 largest holdings

Geographical origin of shareholders

Spain
70.09%
France
0.88%
Switzerland
0.41%
Italy
0.14%
Portugal
0.04%
Germany
0.02%
United Kingdom
0.01%
Ireland
0.01%

Based on 1000 largest holdings

Logo Almirall, S.A.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Employees
2,026
More about the company